. 2004 Mar 23;90(8):1644–1653. doi: 10.1038/sj.bjc.6601707

Table 1. IC₅₀ values and killing efficacy of α-TOS, hrTRAIL, and hrTRAIL plus α-TOS in malignant mesothelioma and nonmalignant mesothelial cell lines.

	α-TOS		hrTRAIL		hrTRAIL_α-TOS
Cell type	IC₅₀ (μM)	Max effect (% cell death)	IC₅₀ (μg ml⁻¹)	Max effect (% cell death)	IC₅₀ (μg ml⁻¹)	Max effect (% cell death)
MM-B1	36±4	96±3	0.3±0.1	64±4	0.010±0.002	87±9
Meso-2	38±7	95±5	5.0±1.0	55±2	0.030±0.004	76±7
Ist-Mes	35±6	96±4	0.7±0.1	32±5	0.100±0.050	69±10
Met-5A	55±8	44±2	0.5±0.1	26±3	0.450±0.150	34±8

The IC₅₀ values for α-TOS, hrTRAIL, and hrTRAIL (50 ng ml⁻¹) plus α-TOS (30 μM) were calculated from dose–response curves of MM and nonmalignant mesothelial cells at 24 h of treatment. Data are expressed as mean±s.d. from three independent experiments.

Table 1. IC50 values and killing efficacy of α-TOS, hrTRAIL, and hrTRAIL plus α-TOS in malignant mesothelioma and nonmalignant mesothelial cell lines.

Table 1. IC₅₀ values and killing efficacy of α-TOS, hrTRAIL, and hrTRAIL plus α-TOS in malignant mesothelioma and nonmalignant mesothelial cell lines.